low-dose computed tomography
Pfizer’s Lorviqua recommended by NICE for lung cancer
Lung cancer is the leading cause of cancer-related deaths worldwide
Boehringer’s Hernexeos granted FDA accelerated approval for lung cancer patients
Approximately 226,650 lung cancer cases are expected to be diagnosed in the US this year
CHMP recommends BeOne Medicines’ Tevimbra for new lung cancer indication
Non-small cell lung cancer accounts for up to 90% of all lung cancer cases
AstraZeneca shares late-stage results for Tagrisso combination in lung cancer
An estimated 2.4 million people globally are diagnosed with lung cancer each year
FDA approves Dizal’s oral therapy Zegfrovy to treat advanced lung cancer
Around 226,650 new cases of lung cancer are expected to be diagnosed in the US this year
MHRA approves Accord Healthcare’s Hetronifly to treat aggressive form of lung cancer
Small cell lung cancer accounts for up to 15% of all lung cancer diagnoses
AstraZeneca/Daiichi Sankyo’s Datroway granted FDA accelerated approval for lung cancer
Approximately 226,650 new cases of lung cancer will be diagnosed in the US this year
Roche/Jazz share positive phase 3 results for lung cancer combination therapy
Approximately 30,000 new cases of small cell lung cancer are reported in the US every year
Bristol Myers Squibb’s perioperative Opdivo regimen granted EC approval in NSCLC
Up to 55% of patients with non-metastatic NSCLC develop recurrence despite curative resection
Pfizer gains rights to 3SBio’s investigational bispecific antibody in deal worth over $6bn
The candidate is in clinical development for colorectal cancer, lung cancer and gynaecological tumours
AbbVie’s Emrelis granted FDA accelerated approval to treat advanced lung cancer
An estimated 226,650 people will be diagnosed with lung cancer in the US this year
BeiGene’s Tevimbra combination granted EC approval in small cell lung cancer
Approximately 15% of all lung cancer patients are diagnosed with the aggressive disease